Eli Lilly Reports Positive Results of Cyramza (ramucirumab) in P-III RELAY Study for mNSCLC
Shots:
- The P-III RELAY study involves assessing of Cyramza + erlotinib vs PBO + erlotinib in 449 patients with EGFR mutated mNSCLC across North America- EU- and Asia
- The P-III RELAY trials resulted in meeting its 1EPs & 2EPs and is safe & effective with no major AEs
- Cyramza (ramucirumab) is an antiangiogenic therapy active against VEGF-2 receptor. Lilly plans to make a global regulatory submission in H2’19 and submitted in the US- EU & Japan for hepatocellular carcinoma
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com